ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SCYX Scynexis Inc

1.77
0.00 (0.00%)
Pre Market
Last Updated: 12:06:50
Delayed by 15 minutes
Share Name Share Symbol Market Type
Scynexis Inc NASDAQ:SCYX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.77 1.77 1.85 0 12:06:50

SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

29/08/2018 1:00pm

PR Newswire (US)


Scynexis (NASDAQ:SCYX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Scynexis Charts.

JERSEY CITY, N.J., Aug. 29, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in the following upcoming investor conferences:

  • Baird's 2018 Global Healthcare Conference at the InterContinental New York Barclay Hotel on Wednesday, September 5, 2018 at 2:00 p.m. ET.
  • The H.C. Wainwright 20th Annual Global Investment Conference at the St. Regis New York on Thursday, September 6, 2018 at 12:30 p.m. ET.
  • The Oppenheimer Fall Summit at the Langham, New York, Fifth Avenue on Wednesday, September 26, 2018.

A live webcast of the Baird and HC Wainwright presentations will be available on the Investors section of the Company's website: www.scynexis.com. Replay of the presentations will be available approximately two hours after each event and will be available for two weeks following each presentation.

About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

CONTACT:

Investor Relations
Natalie Wildenradt
Argot Partners
Tel: 212-600-1902
natalie@argotpartners.com

Media Relations
George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093
george@macbiocom.com

Cision View original content:http://www.prnewswire.com/news-releases/scynexis-inc-to-participate-in-upcoming-investor-conferences-300701931.html

SOURCE SCYNEXIS, Inc.

Copyright 2018 PR Newswire

1 Year Scynexis Chart

1 Year Scynexis Chart

1 Month Scynexis Chart

1 Month Scynexis Chart

Your Recent History

Delayed Upgrade Clock